Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Immunometabolites

Itaconate trims the fat

Inflammation is characterized by cell metabolic reprogramming that can influence the outcome of metabolic syndrome-related diseases such as non-alcoholic fatty liver disease (NAFLD). In this issue, Weiss et al. discover that preventing the production of the immunomodulatory metabolite itaconate increases liver fat accumulation in mouse models of NAFLD and that treatment with itaconate may promote fat oxidation. This study reveals new therapeutic potential for targeting the itaconate metabolic pathway in NAFLD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Decreased itaconate exacerbates NAFLD.

References

  1. Younossi, Z. M. et al. Hepatology 77, 1335–1347 (2023).

    Article  PubMed  Google Scholar 

  2. Michelucci, A. et al. Proc. Natl Acad. Sci. USA 110, 7820–7825 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Cordes, T. et al. J. Biol. Chem. 291, 14274–14284 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Lampropoulou, V. et al. Cell Metab. 24, 158–166 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Shen, H. et al. Cell 171, 771–782.e11 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Bambouskova, M. et al. Nature 556, 501–504 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Mills, E. L. et al. Nature 556, 113–117 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Weiss, J. M. et al. Nat. Metab. https://doi.org/10.1038/s42255-023-00801-2 (2023).

  9. Németh, B. et al. FASEB J. 30, 286–300 (2016).

    Article  PubMed  Google Scholar 

  10. Tran, S. et al. Immunity 53, 627–640.e5 (2020).

    Article  CAS  PubMed  Google Scholar 

  11. Remmerie, A. et al. Immunity 53, 641–657.e14 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Zhang, H. et al. Nat. Metab. 3, 843–858 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Hendrikx, T. et al. J. Hepatol. 77, 1373–1385 (2022).

    Article  CAS  PubMed  Google Scholar 

  14. Hou, J. et al. J. Clin. Invest. 131, e135197 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Zeng, Y. R. et al. J. Clin. Invest. 133, e160463 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Thekla Cordes or Martina Wallace.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Turner, R., Cordes, T. & Wallace, M. Itaconate trims the fat. Nat Metab 5, 915–916 (2023). https://doi.org/10.1038/s42255-023-00819-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s42255-023-00819-6

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research